Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2124156
Abstract: ABSTRACT Introduction Diffuse large B-cell lymphoma (DLBCL) is not a single entity but instead represents a collection of interrelated malignancies having distinct molecular features. Recent multiomics studies have independently identified the presence of at least… read more here.
Keywords: cell lymphoma; large cell; diffuse large; upfront therapy ... See more keywords
MP37-10 ASSOCIATION OF TUMOR BURDEN WITH THE ELIGIBILITY OF UPFRONT THERAPY IN PATIENTS WITH CASTRATION NAIVE PROSTATE CANCER: A MULTICENTER RETROSPECTIVE STUDY
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Urology"
DOI: 10.1097/ju.0000000000000886.010
Abstract: INTRODUCTION AND OBJECTIVE:Although several large-scale studies reported a robust benefit of upfront therapy for mHNPC, not all patients with mHNPC experienced mCRPC progression. As there is a conc... read more here.
Keywords: therapy; burden eligibility; upfront therapy; mp37 association ... See more keywords
Demystifying changes with upfront therapy in Mantle Cell Lymphoma: Global clinician preparedness in the aftermath of educational interventions
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2869
Abstract: Background: In recent decades, standard upfront therapy for mantle cell lymphoma (MCL) has featured chemoimmunotherapy (CIT) regimens of varying intensity followed by autologous transplant in eligible patients. Outcomes with CIT suggest that this strategy can… read more here.
Keywords: btki; mantle cell; cell; upfront therapy ... See more keywords